Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics drive U.S. drug sales growth

Executive Summary

Unbranded drug sales grew 22 percent in 2006, driving U.S. prescription drug sales up 8.3 percent to $274.9 billion during the year. According to IMS Health, which released annual sales figures March 8, strong generic sales were driven by Teva's simvastatin (Zocor), which generated $911 million in sales, and Apotex's generic clopidogrel (Plavix), which brought in $902 million. Medicare Part D was the other major sales growth driver, with prescriptions dispensed through the federal program accounting for 17 percent of retail scripts by the end of the year, IMS says. Biotech segment sales jumped 20 percent to $40.3 billion, driven by Amgen's Aranesp (up 42 percent to $3.9 billion), Enbrel (up 12 percent to $3.1 billion) and Neulasta (up 28 percent to $2.9 billion). Total U.S. prescription volume grew 4.6 percent in 2006 compared to 3.3 percent growth in 2005...

You may also be interested in...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts